Overview

Gender

male

President and CEO of Neuronetics, Chris Thatcher leads the pioneer and innovator in Transcranial Magnetic Stimulation therapy to treat Major Depressive Disorder.
Neuronetics is focused on successfully developing and commercializing non-invasive therapies to treat chronic psychiatric and neurological disorders. Neuronetics is the market leader in TMS with the NeuroStar TMS Therapy System for major depression. Over 23,000 patients have been treated with NeuroStar at notable psychiatric hospitals and institutions, as well as private practices across the country. Backed by the largest clinical data set of any TMS treatment for depression, NeuroStar TMS Therapy is proven effective for patients who have not benefited from prior antidepressant medication, and NeuroStar is the only TMS device to have demonstrated long-term durability of clinical effect over 12 months. Chris is based at Neuronetics Global Headquarters in Malvern, PA and was appointed to his current role in December 2014.